REPORT FROM THE 25th CONGRESS OF THE ECTRIMS Dusseldorf, Germany, September 9-12, 2009 Alemtuzumab (Campath 1H) is a monoclonal antibody that targets CD52, a cell surface molecule found on thymocytes, lymphocytes, monocytes and eosinophils. Early data suggested that the agent could reduce disability (Coles et al. J Neurol 2006; 253: 98-108), which led to the phase II CAMMS223 trial comparing alemtuzumab with beta-interferon-1a (CAMMS223 Investigators. N Engl J Med 2008; 359: 1786-1801).
Read More
Neurology
Vitamin D in MS: update on new studies
December 15, 2009REPORT FROM THE 25th CONGRESS OF THE ECTRIMS Dusseldorf, Germany, September 9-12, 2009 – Three studies at the 25th ECTRIMS congress presented new data on vitamin D and multiple sclerosis.
Trial of surgery for migraine
December 1, 2009A significant proportion of migraine patients are refractory to treatment, although there is a need to adequately define refractory migraine.
Read More
Thyroid medication use linked to AD risk
December 1, 2009A number of recent studies have suggested that hyper- or hypothyroidism is associated with an increased risk of Alzheimers disease.
Read More
Smoking associated with seizure: Nurses’ Health Study II analysis
November 18, 2009A prospective analysis of subjects enrolled in the Nurses’ Health Study II has found that current cigarette smoking is associated with an increased risk of seizures (Dworetzky et al. Epilepsia 2009; epublished August 19, 2009).